Market Outlook

By 2035, the U.S. Neurotechnology Devices Market is expected to reach approximately USD 48.12 billion, expanding at a CAGR of 10.12% during the forecast period from 2026 to 2035. The market was valued at approximately USD 18.35 billion in 2025, with historical analysis covering 2021 to 2024. Values in this report are expressed in USD billions.

The U.S. neurotechnology devices industry is evolving from a collection of specialized neurological products into an integrated clinical technology ecosystem spanning brain sensing, neural stimulation, neurodiagnostic monitoring, neurorehabilitation, precision neurosurgery, neuroprosthetics, and brain-computer interfaces. Market demand is being supported by the increasing prevalence of stroke, epilepsy, Parkinson’s disease, Alzheimer’s disease and related dementias, treatment-resistant depression, chronic neuropathic pain, migraine, traumatic brain injury, spinal cord injury, essential tremor, sleep-related neurological disorders, and other conditions that impair movement, cognition, sensation, communication, or behavioral health.

Neurotechnology adoption in the United States is shifting beyond conventional electroencephalography, spinal cord stimulation, deep brain stimulation, and nerve conduction testing toward closed-loop neuromodulation, responsive neurostimulation, adaptive deep brain stimulation, high-density cortical electrodes, transcranial magnetic stimulation, transcranial electrical stimulation, MRI-guided focused ultrasound, wearable tremor therapy, non-invasive spinal cord stimulation, digital biomarkers, and early-stage implanted brain-computer interfaces. These technologies are creating new clinical pathways for patients who have exhausted medications, conventional rehabilitation, or standard surgical treatment.

The market expanded from approximately USD 11.96 billion in 2021 to USD 16.43 billion in 2024. Estimated market value reached USD 13.19 billion in 2022 and USD 14.67 billion in 2023. Historical growth was supported by the normalization of elective implant procedures after the pandemic, restoration of neurological diagnostic volumes, increasing use of spinal cord stimulation for chronic pain, expansion of outpatient transcranial magnetic stimulation networks, rising deep brain stimulation utilization, and greater health-system investment in advanced epilepsy monitoring and neurosurgical navigation.

In 2025, the market reached approximately USD 18.35 billion as U.S. hospitals, neuroscience institutes, behavioral health providers, pain management groups, rehabilitation centers, and research institutions increased spending on connected neuromodulation platforms, neurophysiology systems, precision surgical technologies, advanced stimulation programming, and remote neurological monitoring. The estimated 2025 market includes medical-grade neuromodulation devices, neurodiagnostic and neurophysiological monitoring systems, neuroprosthetic and neural-interface devices, neuro-specific surgical and navigation technologies, and technology-enabled neurological rehabilitation systems. Standalone pharmaceuticals, general-purpose imaging equipment, and unregulated consumer wellness products are excluded.

The forecast reflects a bottom-up market model based on procedure volumes, capital-system installations, implant replacement cycles, disposable utilization, average selling prices, outpatient treatment sessions, service contracts, software revenue, clinical trial activity, and expected penetration of emerging neural-interface technologies. The forecast assumes continued regulatory progress, incremental reimbursement expansion, increasing neurological disease burden, and wider clinical acceptance of devices that can demonstrate measurable functional or economic benefit.

 

Introduction

According to the U.S. Neurotechnology Devices Market Report, the industry is shaped by a distinctive combination of high neurological disease burden, advanced neurosurgical infrastructure, strong academic research networks, specialist physician concentration, established Medicare and commercial insurance pathways, and an unusually active medical-device innovation environment.

Neurotechnology devices interact directly or indirectly with the central or peripheral nervous system to diagnose neurological dysfunction, measure neural activity, modulate abnormal circuits, restore lost function, or support neurological recovery. These products range from established EEG, electromyography, deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, and intraoperative neuromonitoring systems to emerging cortical interfaces capable of recording hundreds or thousands of neural signals.

The commercial structure of the market is highly diverse. Implantable neuromodulation systems generate high-value procedure revenue and recurring replacement demand. Neurodiagnostic systems combine capital-equipment sales with electrodes, sensors, software, service contracts, and disposable accessories. TMS clinics generate revenue through repeated treatment sessions rather than a single procedure. Neurorehabilitation platforms are evaluated through functional improvement, therapy intensity, therapist productivity, and patient engagement. Brain-computer interface companies remain predominantly in clinical development, but their progress is influencing investment, partnership activity, and long-term competitive positioning.

The need for neurotechnology is being amplified by demographic change. The U.S. population aged 65 and older exceeded 61 million in 2024 and is growing faster than the overall population. This increases the number of patients at risk for stroke, neurodegenerative disease, movement disorders, chronic pain, cognitive impairment, and age-associated functional decline. Aging also expands the Medicare-eligible population, making reimbursement policy and hospital episode economics increasingly important to neurotechnology manufacturers.

Neurological disorders place substantial pressure on the U.S. healthcare system because they frequently require long-term treatment, repeated specialist visits, complex diagnostics, multidisciplinary rehabilitation, caregiver support, and management of progressive disability. More than 795,000 people experience a stroke in the United States each year. Approximately 2.9 million U.S. adults have active epilepsy, while hundreds of thousands of children are also affected. More than 6 million older Americans are estimated to be living with Alzheimer’s disease, and at least one million Americans are affected by Parkinson’s disease.

The addressable patient pool extends beyond traditional neurological diseases. More than 21 million U.S. adults experienced a major depressive episode in 2024. A portion of these patients progress to treatment-resistant depression and may become candidates for TMS, vagus nerve stimulation, implanted investigational systems, or other circuit-based therapeutic approaches. Chronic pain, migraine, sleep apnea, traumatic injury, and spinal cord injury further expand the clinical relevance of neurostimulation and neurological rehabilitation technologies.

Hospital procurement behavior is changing accordingly. Neuroscience service lines are increasingly evaluated as integrated programs that combine diagnostics, intervention, surgery, rehabilitation, and long-term monitoring. Health systems are more likely to approve premium neurotechnology when the investment supports patient referrals, creates a differentiated center of excellence, increases procedure capacity, reduces medication dependence, prevents avoidable hospital utilization, or improves functional outcomes that matter to payers and patients.

From 2026 to 2035, the central strategic transition will be the movement from open-loop device delivery to responsive and personalized neurological care. Products capable of detecting neural activity, interpreting the signal, adjusting therapy, documenting response, and integrating data into clinical workflows will have a stronger value proposition than devices delivering fixed stimulation without actionable feedback.

 

Key Market Drivers: What’s Fueling the U.S. Neurotechnology Devices Market Boom?

The first major driver is the scale and diversity of neurological disease burden in the United States. Disorders affecting the brain, spinal cord, peripheral nerves, and neuromuscular system affect a substantial share of the population and represent a major source of disability. Stroke, dementia, epilepsy, movement disorders, chronic pain, depression, traumatic brain injury, and spinal cord injury generate demand across acute treatment, chronic therapy, diagnostic monitoring, surgery, rehabilitation, and home care.

A second driver is the rapid aging of the U.S. population. Older adults are more likely to experience Parkinson’s disease, essential tremor, dementia, stroke, neuropathic pain, gait impairment, sleep-related disorders, and other conditions that can be diagnosed or treated using neurotechnology. The aging population also increases demand for devices that can preserve independence, reduce caregiver burden, and delay institutional care. Neurotechnology that improves mobility, communication, cognitive function, symptom control, or activities of daily living can therefore generate value extending well beyond the neurological procedure itself.

A third driver is the expansion of neuromodulation into broader indications. Spinal cord stimulation remains the largest implantable neurotechnology segment, but the value pool is diversifying. Deep brain stimulation is becoming more personalized through directional leads, sensing-enabled implants, rechargeable systems, and adaptive stimulation. Vagus nerve stimulation continues to serve refractory epilepsy and selected depression populations. Responsive neurostimulation is enabling real-time seizure detection and therapy delivery. Peripheral nerve stimulation is expanding across postoperative pain, chronic musculoskeletal pain, neuropathic pain, and rehabilitation-related applications.

A fourth driver is the increasing incidence of treatment failure within conventional care pathways. Large numbers of U.S. patients do not achieve adequate symptom control from medications, behavioral therapy, physical rehabilitation, injections, or conventional surgery. Device manufacturers are targeting these treatment gaps with therapies designed for refractory disease. The commercial opportunity is particularly strong when the technology is positioned after clearly defined treatment failure, supported by clinical guidelines, and aligned with an established reimbursement pathway.

A fifth driver is the shift toward non-opioid chronic pain management. U.S. providers and payers continue to seek alternatives capable of reducing long-term dependence on opioids or repeated invasive procedures. Spinal cord stimulation, dorsal root ganglion stimulation, peripheral nerve stimulation, restorative neurostimulation, and wearable electrical stimulation are increasingly evaluated within multidisciplinary pain pathways. Purchasing decisions depend on durable pain relief, functional improvement, revision rates, explant rates, programming burden, and total cost over the life of the device.

A sixth driver is the expansion of outpatient neurological care. TMS, peripheral nerve stimulation, ambulatory EEG, remote seizure monitoring, sleep-related neurostimulation follow-up, and selected pain procedures are moving into physician offices, outpatient departments, specialty clinics, and ambulatory surgery centers. This transition expands access but changes product requirements. Outpatient buyers prioritize smaller footprints, predictable utilization, lower staffing intensity, rapid setup, reimbursement support, and simplified service models.

A seventh driver is the strengthening of the U.S. research and regulatory ecosystem. The country has a high concentration of neuroscience laboratories, academic medical centers, engineering programs, clinical trial sites, neurotechnology start-ups, and venture investors. Federal initiatives have supported development of high-resolution neural recording, circuit mapping, neuroprosthetics, adaptive stimulation, and neuroethics frameworks. FDA guidance for implanted brain-computer interfaces has also created greater development-pathway visibility for companies targeting paralysis or amputation.

An eighth driver is the ability of advanced neurotechnology to create differentiated hospital service lines. Comprehensive epilepsy centers, movement-disorder programs, neuromodulation clinics, pain institutes, stroke centers, and neurorehabilitation facilities use advanced technology to recruit specialists and capture regional referrals. High-value devices can be economically attractive when they generate downstream imaging, surgery, programming, rehabilitation, and follow-up activity.

A ninth driver is greater acceptance of objective neurological data. Neurology has historically depended heavily on clinical examination and patient-reported symptoms. The market is now moving toward quantitative EEG, digital biomarkers, electrophysiological signatures, continuous neural sensing, gait analytics, speech analytics, sleep measurements, and algorithm-supported interpretation. Technologies that convert neurological behavior into reproducible data can improve patient selection, therapy adjustment, and evidence generation.

The final major driver is platform consolidation. Hospitals increasingly prefer vendors capable of supporting multiple procedures, standardized programming, shared service infrastructure, remote support, and data integration. This is creating an advantage for companies with broad neuromodulation or neurodiagnostic portfolios while also creating acquisition opportunities for smaller companies with differentiated electrodes, sensors, stimulation waveforms, software, or clinical indications.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. neurotechnology devices market is becoming more focused on neural specificity, closed-loop response, reduced invasiveness, patient usability, and measurable functional outcomes. The next generation of devices is expected to sense neurological signals continuously, identify clinically meaningful patterns, and adjust treatment in real time.

Adaptive deep brain stimulation represents one of the most important advances. Conventional DBS typically delivers stimulation according to parameters programmed during clinic visits. Adaptive systems can use neurological biomarkers to modify stimulation based on changing symptoms or brain activity. This may reduce unnecessary stimulation, improve symptom control, extend battery life, and decrease the programming burden for movement-disorder specialists.

Directional stimulation is also improving therapeutic precision. Segmented electrodes allow clinicians to steer electrical current toward intended neural targets and away from structures associated with adverse effects. This can expand the therapeutic window and make device programming more individualized. Competition is increasingly shifting from the implant alone toward the full platform, including leads, implantable pulse generators, sensing capability, programming software, imaging integration, remote support, and clinical education.

Closed-loop epilepsy treatment is another defining innovation area. Responsive neurostimulation systems monitor electrical activity and deliver stimulation when patterns associated with seizure onset are detected. Advances in intracranial recording, cloud analytics, electrode design, and seizure-localization software are improving the ability to understand refractory epilepsy. These technologies can also generate longitudinal datasets that support clinical decision-making beyond the immediate stimulation response.

Non-invasive brain stimulation is expanding across behavioral health and neurological care. TMS systems are becoming faster, more targeted, and more operationally efficient. Accelerated protocols, theta-burst stimulation, deeper stimulation geometries, improved coil positioning, and digital treatment planning can reduce the time required per session and increase daily clinic capacity. This is strategically important because TMS economics depend on patient throughput, treatment completion, payer authorization, and technician utilization.

MRI-guided focused ultrasound is creating a non-incisional treatment pathway for selected movement-disorder patients. The technology uses image guidance and focused acoustic energy to create a therapeutic lesion without opening the skull. It is particularly relevant for patients with medication-refractory tremor who are unwilling or unsuitable for implanted stimulation. Continued indication expansion could position focused ultrasound as a larger competitor within advanced movement-disorder treatment.

High-density cortical interfaces are advancing the brain-computer interface field. New electrode arrays are being designed to record neural signals with greater spatial resolution while using thinner, more flexible materials. Some platforms are intended for temporary clinical recording and brain mapping, while others are being developed for long-term implantation and communication control. The commercial significance extends beyond paralysis because neural-interface technology may eventually support movement restoration, speech decoding, sensory feedback, cognitive monitoring, and closed-loop therapeutic stimulation.

Spinal cord injury innovation is moving into non-invasive stimulation. Transcutaneous spinal cord stimulation can be paired with task-specific rehabilitation to improve strength, sensation, or motor function without implantation. This creates opportunities for rehabilitation hospitals, academic centers, and specialty clinics that cannot support invasive neurosurgical programs. It also demonstrates the broader convergence between neurostimulation and physical rehabilitation.

Wearable neurotechnology is becoming more clinically credible. Wrist-worn tremor therapy, wearable electrical stimulation, gait sensors, seizure-detection wearables, and home neurorehabilitation devices are being developed to deliver or monitor therapy outside the hospital. The strongest products will be those that demonstrate clinical benefit, sustain patient adherence, and integrate usable information into physician workflows rather than simply generating consumer data.

Artificial intelligence is becoming a strategic layer across neurotechnology. AI can support seizure detection, EEG interpretation, neural signal decoding, stimulation optimization, surgical planning, patient selection, and remote monitoring prioritization. However, hospitals will require evidence that algorithms perform consistently across patient populations, devices, and care settings. Manufacturers must also address cybersecurity, software updates, data ownership, bias, and regulatory control of adaptive algorithms.

Manufacturers are raising the commercial bar through stronger evidence generation. U.S. providers increasingly expect randomized trials, comparative effectiveness data, real-world evidence, functional endpoints, patient-reported outcomes, and health-economic models. A technology that produces statistically significant neurological change but does not improve daily function, reduce care utilization, or simplify clinical workflow may struggle to achieve broad adoption.

 

Segmentation Insights

The U.S. Neurotechnology Devices Market is segmented on the basis of product category, application, end user, technology type, and region.

 

By Product Category

Neuromodulation and Neurostimulation Devices

Neuromodulation and neurostimulation devices represented the largest product category, with an estimated value of approximately USD 7.22 billion in 2025. The category includes spinal cord stimulators, deep brain stimulators, vagus nerve stimulators, responsive neurostimulation systems, peripheral nerve stimulators, sacral neuromodulation products used in neurologically mediated dysfunction, restorative neurostimulation, and related leads, programmers, trial systems, chargers, and surgical accessories.

Spinal cord stimulation accounts for the largest portion of category revenue because of the scale of chronic pain treatment and the high value of implantable systems. Growth is being driven by new waveforms, closed-loop sensing, smaller implants, rechargeable and recharge-free options, improved trial conversion, and expansion into painful diabetic neuropathy and non-surgical back pain. The segment remains commercially attractive but faces scrutiny regarding explant rates, long-term durability, patient selection, and comparative value.

DBS is smaller by volume but strategically important because it combines premium implants, replacement cycles, complex programming, and specialist-led care. Adaptive stimulation, sensing-enabled systems, directional leads, improved imaging, and rechargeable batteries are expected to support above-average growth through 2035.

Neurodiagnostic and Neurophysiological Monitoring Devices

Neurodiagnostic and monitoring systems generated an estimated USD 4.15 billion in 2025. This segment includes EEG systems, ambulatory EEG, intracranial EEG, EMG, evoked-potential systems, nerve-conduction systems, cerebral oximetry, intraoperative neuromonitoring, sleep-related neurodiagnostic systems, electrodes, amplifiers, recording software, and neurological data-management platforms.

Demand is supported by epilepsy diagnosis, seizure localization, sleep disorders, neuromuscular disease, critical-care monitoring, surgical risk management, and brain-function assessment. Capital equipment generates a stable installed base, while electrodes, sensors, service agreements, software upgrades, and disposable accessories provide recurring revenue.

Ambulatory and home-based EEG represent important growth opportunities because long-term monitoring may capture neurological events that are missed during short inpatient studies. Health systems are also investing in remote interpretation and cloud-enabled workflows to address neurologist and neurophysiology staffing constraints.

Neurosurgical, Navigation, and Brain-Mapping Systems

Neurosurgical and navigation technologies represented approximately USD 2.90 billion in 2025. This segment includes stereotactic systems, neuro-navigation platforms, robotic neurosurgical guidance, surgical planning software, intraoperative brain mapping, cortical electrodes, neuroendoscopy support, cranial access systems, and functional neurosurgery instrumentation.

Demand is concentrated in academic hospitals, comprehensive neuroscience centers, pediatric hospitals, and high-volume neurosurgical programs. Procurement decisions are closely tied to surgical accuracy, operating-room integration, procedure time, compatibility with imaging, and the ability to support multiple cranial or spinal procedures.

The segment is benefiting from image fusion, tractography, AI-assisted planning, robotic trajectory placement, and higher-resolution cortical recording. Vendors that integrate planning, navigation, stimulation, and outcome documentation into a unified workflow are positioned to gain purchasing preference.

Neuroprosthetics and Brain-Computer Interface Devices

Neuroprosthetics and brain-computer interface devices represented an estimated USD 1.58 billion in 2025, including commercially available neural prosthetic systems, cortical and peripheral interfaces, sensory restoration technologies, communication interfaces, research-grade neural recording platforms, and early clinical BCI systems.

Most implanted BCI technologies remain in feasibility-stage clinical development and do not yet contribute substantial routine-care revenue. However, the segment is expected to achieve the highest long-term CAGR as companies progress from temporary recording and research platforms toward implanted communication, movement, and sensory-restoration applications.

Near-term commercial value will be generated by clinical research systems, high-density electrodes, surgical accessories, signal-processing platforms, and partnerships with academic medical centers. Longer-term value will depend on implantation safety, signal stability, decoding performance, home usability, reimbursement, and clear improvement in communication or independence.

Neurorehabilitation and Wearable Neurotechnology

Neurorehabilitation and wearable neurotechnology generated approximately USD 2.50 billion in 2025. Products include robotic rehabilitation systems, functional electrical stimulation devices, transcutaneous spinal stimulation, gait-training technologies, wearable tremor therapy, seizure-detection wearables, home neurorehabilitation platforms, and sensor-enabled movement-analysis systems.

Stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, cerebral palsy, and neurodegenerative conditions create substantial demand for technologies that can improve rehabilitation intensity or functional recovery. The segment is moving from capital-intensive robotic systems toward portable and home-compatible platforms that extend therapy beyond formal clinic sessions.

Commercial success depends on whether the device improves measurable function rather than simply increasing activity. Products must fit therapist workflows, support patient adherence, and produce documentation that can justify reimbursement or institutional investment.

 

By Application

Chronic Pain and Migraine Management

Chronic pain and migraine represented the largest application segment, valued at an estimated USD 5.05 billion in 2025. Spinal cord stimulation, peripheral nerve stimulation, restorative neurostimulation, wearable electrical stimulation, and non-invasive nerve stimulation are increasingly incorporated into treatment pathways for refractory pain.

Growth is being shaped by demand for non-opioid therapy, expansion of neuromodulation indications, rising pain-center capacity, and migration of trial procedures into outpatient settings. Manufacturers are differentiating through waveform design, closed-loop control, smaller implant size, simplified charging, MRI compatibility, remote programming, and evidence supporting functional improvement.

Payer requirements remain a major market variable. Prior authorization, psychological assessment, documented conservative-therapy failure, trial success, and long-term outcome expectations can limit patient conversion. Companies that help providers identify appropriate patients and document outcomes will have a stronger commercial position.

Movement Disorders and Neurodegenerative Diseases

Movement disorders and neurodegenerative diseases accounted for an estimated USD 4.36 billion in 2025. The application includes Parkinson’s disease, essential tremor, dystonia, Alzheimer’s disease, other dementias, and selected gait or motor-control disorders.

DBS, focused ultrasound, wearable tremor therapy, gait-analysis systems, cognitive assessment technologies, and neurophysiological monitoring are central product categories. Parkinson’s disease and essential tremor currently provide the strongest device-based revenue, while dementia-related neurotechnology remains more diagnostic, investigational, and monitoring-focused.

The aging population will expand the addressable patient pool, but adoption will depend on earlier referral and improved awareness. Many patients who may qualify for advanced movement-disorder therapy are referred late or never evaluated at a specialized center. Manufacturers that support referral education and multidisciplinary program development can expand the treated market.

Epilepsy and Seizure Management

Epilepsy and seizure management represented approximately USD 2.48 billion in 2025. The segment includes EEG, ambulatory EEG, intracranial monitoring, responsive neurostimulation, vagus nerve stimulation, cortical electrodes, seizure-detection software, and wearable monitoring technologies.

Approximately 2.9 million U.S. adults and more than 450,000 children have active epilepsy. A clinically significant portion of patients do not achieve adequate seizure control with medication, creating demand for advanced diagnostics, surgery, implantable stimulation, and long-duration monitoring.

Comprehensive epilepsy centers are the primary adopters of intracranial monitoring and responsive stimulation. Community providers contribute demand for routine and ambulatory EEG. Growth will be supported by improved seizure localization, expanded remote monitoring, better referral pathways, and longitudinal data collected through implanted systems.

Psychiatric and Behavioral Health Disorders

Psychiatric and behavioral health applications generated an estimated USD 2.70 billion in 2025. TMS represents the largest established device-based category, primarily serving patients with major depressive disorder who have not achieved adequate benefit from medication or psychotherapy. Additional applications include obsessive-compulsive disorder, smoking cessation, and investigational treatment of post-traumatic stress disorder, addiction, bipolar depression, and other circuit-based conditions.

The U.S. behavioral health market provides a large potential patient base, but utilization remains constrained by payer authorization, treatment-session requirements, geographic access, and patient completion rates. Faster treatment protocols and improved clinic workflow could materially increase penetration.

Implanted psychiatric neuromodulation remains limited, although vagus nerve stimulation is used in selected treatment-resistant depression patients and multiple companies are investigating closed-loop or targeted stimulation approaches. Future commercial expansion will depend on durable clinical benefit and carefully defined patient-selection criteria.

Stroke, Traumatic Brain Injury, Spinal Cord Injury, and Rehabilitation

Stroke, TBI, SCI, and neurological rehabilitation represented approximately USD 3.76 billion in 2025. The segment includes neurodiagnostic monitoring, rehabilitation robotics, functional electrical stimulation, transcutaneous spinal stimulation, gait systems, communication interfaces, cortical recording, and home therapy technologies.

More than 795,000 strokes occur annually in the United States, while approximately 68,000 TBI-related deaths were recorded in 2023. These conditions create substantial demand for acute monitoring and long-term functional restoration.

The commercial opportunity is moving toward technologies that extend the recovery window and deliver higher therapy intensity without proportionally increasing labor. Non-invasive stimulation paired with task practice, sensor-based home rehabilitation, robotic assistance, and BCI-supported communication could become major growth areas if clinical benefit is translated into practical reimbursement pathways.

 

By End User

Hospitals and Integrated Health Systems

Hospitals and health systems are the dominant end users, accounting for an estimated USD 9.25 billion in 2025. They purchase high-value implantable systems, EEG and EMG platforms, intraoperative monitoring equipment, neuro-navigation systems, cortical electrodes, focused ultrasound systems, and rehabilitation technologies.

Large integrated delivery networks use value-analysis committees and enterprise contracting to standardize vendors. Procurement decisions consider clinical outcomes, physician preference, service reliability, capital utilization, disposable costs, cybersecurity, training requirements, and reimbursement.

System-affiliated hospitals are particularly influential because purchasing decisions can be extended across multiple facilities. Manufacturers increasingly require enterprise contracting, clinical education teams, field support, and inventory-management capability to secure these accounts.

Academic Medical Centers and Neuroscience Specialty Centers

Academic medical centers and specialist neuroscience institutes are strategically important early adopters. They lead clinical trials, operate comprehensive epilepsy and movement-disorder programs, train neurosurgeons and neurologists, and evaluate emerging BCI, adaptive stimulation, and neurorehabilitation technologies.

These centers may represent a smaller share of overall procedure volume than the combined community-hospital market, but their influence on evidence generation and referral patterns is disproportionate. Successful adoption at leading institutions can support broader commercial diffusion.

Ambulatory Surgery Centers and Outpatient Specialty Clinics

ASCs and outpatient clinics are gaining share in pain neuromodulation, peripheral nerve stimulation, diagnostic neurophysiology, and TMS. Their estimated 2025 market contribution was approximately USD 1.75 billion.

Products designed for these settings must deliver predictable economics, rapid patient turnover, limited infrastructure requirements, and dependable reimbursement. Outpatient buyers generally have lower tolerance for complex service agreements or underutilized capital systems than major hospitals.

Diagnostic Laboratories, Neurology Practices, and Behavioral Health Networks

Diagnostic laboratories, neurology practices, sleep centers, and behavioral health networks represented approximately USD 2.25 billion in 2025. They are major users of EEG, EMG, nerve-conduction, ambulatory monitoring, TMS, cognitive assessment, and neurological software.

TMS networks are consolidating in some markets as operators seek scale in payer contracting, scheduling, patient acquisition, and equipment utilization. Ambulatory neurodiagnostic providers are similarly investing in remote interpretation and cloud-based workflow tools.

Rehabilitation Facilities, Home Care, and Research Institutions

Rehabilitation hospitals, physical therapy networks, home-care programs, universities, government research laboratories, and clinical research organizations represented approximately USD 1.75 billion in 2025.

This group is expected to record strong growth as wearable and home-compatible neurotechnology becomes more clinically validated. Research institutions will remain important buyers of high-density neural recording, BCI, stimulation, and signal-processing systems, while rehabilitation providers will prioritize devices that extend therapy and improve labor productivity.

 

By Technology Type

Invasive Implantable Neurotechnology

Implantable technologies dominated the market, generating an estimated USD 7.65 billion in 2025. This category includes spinal cord stimulation, deep brain stimulation, responsive neurostimulation, vagus nerve stimulation, peripheral nerve stimulation, restorative stimulation, and implanted neural interfaces.

Implantables command high selling prices and generate recurring revenue through replacements, revisions, leads, accessories, and programming. Growth will be strongest for sensing-enabled devices, closed-loop systems, smaller implants, extended-life batteries, and platforms with stronger long-term evidence.

Non-Invasive Neurotechnology

Non-invasive technologies represented approximately USD 4.45 billion in 2025. The segment includes TMS, transcranial electrical stimulation, wearable nerve stimulation, EEG, EMG, external spinal stimulation, and sensor-based neurological monitoring.

Non-invasive products can access larger patient populations because they avoid surgery. However, value per treatment may be lower, and commercial success often depends on repeated use, clinic throughput, patient adherence, or recurring consumables.

Minimally Invasive and Image-Guided Technologies

Minimally invasive and image-guided neurotechnologies generated approximately USD 2.25 billion in 2025. The category includes focused ultrasound, stereotactic procedures, temporary cortical electrodes, percutaneous nerve stimulation, and image-guided functional neurosurgery.

These technologies occupy an important position between conventional surgery and completely non-invasive therapy. They are attractive when they reduce hospitalization or eliminate permanent implantation without compromising clinical effectiveness.

Wearable and Portable Neurotechnology

Wearable and portable platforms represented approximately USD 2.15 billion in 2025. Products include tremor-control wearables, seizure-monitoring devices, portable EEG, gait sensors, home rehabilitation systems, and wearable electrical stimulators.

Adoption will depend on whether devices maintain engagement over time and provide clinically meaningful data. Products that require substantial manual data interpretation or fail to integrate into clinician workflows may face limited sustained utilization.

Software-Enabled and Closed-Loop Neurotechnology

Software-dominant and closed-loop platforms represented an estimated USD 1.85 billion in 2025 when classified by their primary technology architecture. This includes neural signal analytics, algorithm-supported diagnostics, treatment-planning software, digital biomarkers, adaptive stimulation control, and BCI decoding platforms.

Software will influence a larger portion of total device value than its standalone revenue suggests. It can determine therapy personalization, data usability, competitive differentiation, and switching costs. Over time, software performance may become as important as electrode or implant design.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Neurotechnology Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance differs according to population size, neurological disease burden, age distribution, hospital density, specialist availability, pain-treatment infrastructure, academic research concentration, reimbursement mix, and adoption of emerging medical technology.

The South represented the largest regional market in 2025, while the West is expected to achieve the fastest growth through 2035. The Northeast remains the most research-intensive and clinically influential region. The Midwest provides a stable base of neuromodulation, neurodiagnostic, and neurological rehabilitation demand supported by major health systems and an established medical-device ecosystem.

South

The South accounted for an estimated USD 6.42 billion in 2025 and is projected to reach approximately USD 16.80 billion by 2035. The region includes Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, Texas, and the District of Columbia.

The South’s leadership is supported by population scale, rapid metropolitan growth, a large Medicare population, elevated stroke and chronic disease burden in multiple states, extensive pain-management activity, and expanding health-system networks. Several Southern states form part of the historically recognized Stroke Belt, increasing demand for acute neurological care, rehabilitation, monitoring, and secondary prevention infrastructure.

Texas is the region’s largest state-level opportunity. Houston, Dallas-Fort Worth, Austin, and San Antonio support large academic hospitals, neurosurgical centers, rehabilitation networks, veteran populations, and specialty pain practices. Texas combines high patient volume with substantial geographic variation in access, creating demand for both advanced urban neuroscience programs and portable or remote neurological technologies.

Florida is particularly important because of its older population. The state supports strong demand for movement-disorder treatment, DBS, focused ultrasound, neurodiagnostics, stroke rehabilitation, pain neuromodulation, sleep-related stimulation, and home monitoring. Miami, Tampa, Orlando, Jacksonville, and South Florida’s retirement markets are expected to remain important commercial centers.

North Carolina contains a strong combination of academic research, biotechnology activity, neurological clinical trials, and rapidly growing metropolitan populations. The Research Triangle and major provider systems create opportunities for advanced stimulation, BCI research, neurodiagnostics, and rehabilitation technologies.

Georgia, Tennessee, Maryland, and Virginia have influential academic and integrated health systems. Atlanta and Nashville are major healthcare business centers, while Maryland and Virginia benefit from proximity to federal research agencies, military medicine, veteran care, and the Washington metropolitan technology ecosystem.

South Carolina, Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, and West Virginia have significant neurological disease and disability burdens but more variable access to subspecialty care. Manufacturers can address these states through regional referral centers, tele-neurology integration, portable diagnostics, remote monitoring, and rehabilitation technologies that reduce travel requirements.

Delaware and the District of Columbia are smaller markets by population but benefit from concentrated hospital infrastructure and access to larger Mid-Atlantic referral networks. The South is expected to remain the largest regional market because it combines population growth, unmet clinical need, outpatient procedure expansion, and increasing capital investment by multi-state health systems.

West

The West represented approximately USD 4.15 billion in 2025 and is projected to reach approximately USD 12.55 billion by 2035, producing the fastest regional growth rate. The region includes California, Oregon, Washington, Arizona, Nevada, Idaho, Montana, Wyoming, Colorado, New Mexico, Utah, Alaska, and Hawaii.

California is the dominant state market. It combines the country’s largest state population with academic neuroscience centers, large integrated delivery networks, major technology companies, medical-device developers, venture investors, and BCI start-ups. California is especially important for cortical interfaces, AI-enabled neurological data analysis, digital biomarkers, robotic rehabilitation, and decentralized clinical trials.

The San Francisco Bay Area, Los Angeles, San Diego, and Sacramento each support distinct commercial opportunities. The Bay Area is highly influential in neural interfaces, software, and venture-backed innovation. Los Angeles has major neurosurgical, epilepsy, rehabilitation, and behavioral health programs. San Diego supports medical-device development and clinical research, while Sacramento and inland markets create opportunities for regional referral and outpatient expansion.

Washington and Oregon have sophisticated integrated health systems and strong adoption of connected care. Seattle is an important center for neuroscience research, rehabilitation, and technology development. Oregon’s coordinated provider models can support devices that demonstrate measurable population-health or functional benefits.

Arizona and Nevada are high-growth markets because of population inflows and expanding older-adult populations. Phoenix, Tucson, Las Vegas, and Reno are adding specialty capacity in movement disorders, pain management, stroke care, and rehabilitation. These states are likely to increase demand for DBS, spinal cord stimulation, focused ultrasound, TMS, and ambulatory neurodiagnostics.

Colorado and Utah combine fast-growing metropolitan areas with research-oriented health systems. Denver, Boulder, and Salt Lake City are relevant markets for neurotechnology trials, digital health, rehabilitation, pain treatment, and enterprise hospital procurement.

Idaho, Montana, Wyoming, Alaska, and New Mexico have lower population density and specialist-access constraints. Portable EEG, remote neurological monitoring, home rehabilitation, telehealth-compatible systems, and technologies requiring fewer specialist visits could have disproportionate value in these states.

Hawaii is a smaller but strategically distinct market because of geographic isolation and an aging population. Technologies that reduce travel between islands or support remote neurological care may receive greater attention than conventional high-footprint infrastructure.

The West is expected to gain national market share through 2035 because it links clinical adoption with engineering, software, venture capital, and BCI development. It is likely to remain the leading launch region for neural interfaces and data-intensive neurological platforms.

Northeast

The Northeast accounted for approximately USD 4.48 billion in 2025 and is forecast to reach nearly USD 10.95 billion by 2035. The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Maine, Vermont, New Hampshire, and Rhode Island.

New York is the largest market in the Northeast. New York City contains major academic hospitals, comprehensive epilepsy centers, movement-disorder institutes, rehabilitation programs, and behavioral health networks. Upstate New York adds regional health systems, university hospitals, and community-based demand for pain neuromodulation and neurodiagnostics.

Massachusetts is one of the most influential neurotechnology states despite its smaller population. Boston’s concentration of academic medicine, neuroscience research, biotechnology, engineering, venture investment, and specialized clinical programs makes the state a major center for early-stage device evaluation and BCI development.

Pennsylvania has a large and diverse patient base supported by academic centers in Philadelphia and Pittsburgh, integrated health systems, rehabilitation institutions, and medical-device research. The state is important for epilepsy monitoring, movement disorders, neurosurgery, pain intervention, and post-stroke rehabilitation.

New Jersey benefits from its proximity to New York and Philadelphia, its life-sciences industry, dense healthcare infrastructure, and large older population. Connecticut has strong academic and community hospital systems and access to the wider Boston–New York healthcare corridor.

Maine, Vermont, and New Hampshire have older populations and rural access challenges. Their market opportunity is concentrated in portable diagnostics, remote monitoring, home rehabilitation, and regional referral relationships. Rhode Island is smaller but benefits from concentrated academic and hospital infrastructure.

Northeast procurement is generally evidence-intensive. Academic committees and integrated systems often require strong comparative data, cybersecurity review, workflow analysis, and economic justification. Adoption may therefore be slower initially, but successful placement at leading Northeast institutions can influence national clinical acceptance.

The region will remain central to clinical trials, neurotechnology investment, physician training, and guideline development. Growth will be somewhat slower than in the West because of greater market maturity, but revenue per procedure and adoption of premium technologies will remain high.

Midwest

The Midwest represented approximately USD 3.30 billion in 2025 and is projected to reach approximately USD 7.82 billion by 2035. The region includes Illinois, Indiana, Michigan, Ohio, Wisconsin, Minnesota, Iowa, Missouri, Kansas, Nebraska, North Dakota, and South Dakota.

Illinois is the region’s largest state market, led by Chicago’s academic and community provider ecosystem. Demand spans advanced neurosurgery, epilepsy, movement disorders, behavioral health, pain management, and neurological rehabilitation.

Ohio has multiple nationally recognized hospital systems and substantial neurological procedure capacity. Cleveland, Columbus, and Cincinnati support DBS, neurodiagnostics, neurosurgical navigation, pain neuromodulation, stroke care, and rehabilitation.

Michigan and Indiana provide large procedure bases supported by aging populations, manufacturing economies, and established hospital networks. Detroit, Ann Arbor, Grand Rapids, Indianapolis, and other metropolitan areas are important markets for implantable neurostimulation and neurological diagnostics.

Minnesota is strategically important because of its medical-device industry, engineering expertise, and history in implantable stimulation. The state remains influential in product development, manufacturing, clinical research, and specialist care.

Wisconsin and Missouri offer stable hospital-based demand, while Iowa, Kansas, and Nebraska support regional referral centers serving wide geographic areas. North Dakota and South Dakota are smaller markets where remote diagnostics, portable monitoring, and home-compatible rehabilitation systems can address access constraints.

The Midwest is likely to grow more steadily than the West or South. Hospitals in the region frequently prioritize service reliability, long-term clinical relationships, cost-effective contracting, and practical workflow integration. Manufacturers with strong field support and evidence of durable outcomes are well positioned.

 

Key Market Players

The U.S. Neurotechnology Devices Competitive Landscape is moderately consolidated in established neuromodulation and neurodiagnostic categories but highly fragmented in wearable neurotechnology, peripheral nerve stimulation, neurorehabilitation, and brain-computer interfaces.

Large manufacturers compete through broad implant portfolios, extensive physician training, clinical evidence, reimbursement support, and hospital contracting. Specialized companies compete through differentiated waveforms, disease-specific indications, proprietary electrodes, non-invasive delivery, neural decoding, or targeted rehabilitation applications.

Some of the key participants in the U.S. Neurotechnology Devices Market include Medtronic, Abbott, Boston Scientific Corporation, Stryker Corporation, LivaNova, Inspire Medical Systems, NeuroPace, Globus Medical and Nevro, Integra LifeSciences, Natus Medical, Nihon Kohden America, Compumedics, Neuronetics, BrainsWay, Insightec, SPR Therapeutics, Nalu Medical, Saluda Medical, Cala Health, ONWARD Medical, Synchron, Neuralink, Precision Neuroscience, Blackrock Neurotech, and SetPoint Medical.

Medtronic, Abbott, and Boston Scientific hold strong positions in implantable neuromodulation. Their competitive advantages include broad portfolios, established clinical relationships, programming platforms, global service capability, and substantial evidence-generation resources.

LivaNova and NeuroPace are differentiated through vagus nerve and responsive neurostimulation platforms. Inspire Medical Systems has built a major neurostimulation-based market in obstructive sleep apnea, demonstrating how targeted nerve stimulation can create a large device category when supported by clear patient selection and specialist referral pathways.

Neuronetics and BrainsWay compete in non-invasive behavioral health stimulation. Their commercial performance depends on installed-system growth, treatment utilization, payer coverage, referral generation, and the operational performance of TMS clinics.

Insightec has established MRI-guided focused ultrasound as an alternative for selected movement-disorder patients. Stryker and Integra participate through neurosurgical technologies, cranial products, navigation, and related procedural infrastructure.

Natus Medical, Nihon Kohden America, and Compumedics are important in neurological diagnostics, EEG, sleep, neurophysiology, and monitoring. Their positions are influenced by installed base, signal quality, software workflow, interoperability, service coverage, and recurring electrode or accessory revenue.

SPR Therapeutics, Nalu Medical, Saluda Medical, and Cala Health represent differentiated approaches to peripheral, spinal, or wearable stimulation. ONWARD Medical is advancing spinal cord stimulation for functional recovery after spinal cord injury.

Synchron, Neuralink, Precision Neuroscience, and Blackrock Neurotech are central to the emerging U.S. neural-interface ecosystem. These companies use different implantation methods, electrode designs, channel architectures, signal-processing strategies, and clinical-development models. Their long-term market positions will depend on implantation risk, signal longevity, functional benefit, manufacturability, regulatory progress, and reimbursement readiness.

SetPoint Medical represents the emerging field of bioelectronic medicine, where neural stimulation is used to influence inflammatory pathways. This field could expand the neurotechnology market beyond traditional neurological indications if clinical and commercial evidence develops successfully.

Market share through 2035 will be influenced by FDA approvals, indication expansion, reimbursement, trial outcomes, implant reliability, physician training, software capability, cybersecurity, service quality, and real-world functional outcomes. Companies able to demonstrate both clinical improvement and care-delivery efficiency will be best positioned to maintain premium pricing.

 

Recent Developments

Recent developments in the U.S. Neurotechnology Devices Market show a clear movement toward adaptive stimulation, non-invasive functional restoration, high-density neural recording, and broader acceptance of circuit-based treatment.

In February 2025, the FDA approved an adaptive deep brain stimulation programming feature for a sensing-enabled DBS platform. The approval marked an important transition from continuously delivered stimulation toward therapy that can respond to neurological signals. Adaptive DBS is expected to influence future hospital purchasing, programming workflows, and competitive expectations across movement-disorder platforms.

In 2025, the FDA expanded the intended use of an MRI-guided focused ultrasound system for selected patients with advanced Parkinson’s disease. The expansion strengthened the commercial position of non-incisional therapy within functional neurosurgery and created an additional treatment option for patients experiencing medication-refractory motor complications.

High-density cortical interfaces also advanced. A thin-film, 1,024-electrode cortical array received U.S. clearance for temporary recording, monitoring, and stimulation of electrical signals on the brain’s surface. Although the device is not a permanent implanted BCI, the clearance represents a significant step in the clinical translation of higher-channel-count neural interfaces.

In December 2024, the FDA granted De Novo classification to a transcutaneous spinal stimulation system intended to be used with functional task practice to improve hand strength and sensation in individuals with chronic incomplete cervical spinal cord injury. This development expanded the recognized clinical role of non-invasive spinal stimulation and may support greater investment in neurorehabilitation technologies.

The FDA and NIH have also increased attention to clinical outcome assessment for implanted brain-computer interfaces. This is strategically important because BCI developers must demonstrate benefits that extend beyond signal acquisition. Communication speed, independence, caregiver burden, device usability, reliability, and patient-defined functional improvement are likely to become critical endpoints.

TMS providers continue to adopt shorter treatment protocols and higher-throughput clinic models. Consolidation among behavioral health operators is increasing the importance of payer contracting, standardized protocols, centralized patient scheduling, and equipment utilization.

Pain neuromodulation competition remains intense. Manufacturers are investing in closed-loop spinal cord stimulation, peripheral nerve stimulation, remote programming, and indication expansion. Commercial differentiation is increasingly based on durable functional improvement, reduced charging burden, lower revision rates, and evidence supporting use earlier in the pain-treatment pathway.

BCI companies are advancing U.S. feasibility studies involving people with paralysis. While routine commercialization remains several years away, progress in implantation techniques, wireless communication, signal decoding, and home use is attracting strategic investment. The field is expected to remain clinically selective during the forecast period, but even limited penetration could generate substantial value because of the complexity and high potential benefit of implanted systems.

 

Conclusion

The U.S. Neurotechnology Devices Market Size & Share is positioned to expand from approximately USD 18.35 billion in 2025 to USD 48.12 billion by 2035, supported by a 10.12% CAGR between 2026 and 2035.

The market’s long-term strength is grounded in the growing burden of neurological and behavioral health disorders, an aging population, unmet need among treatment-resistant patients, increased demand for non-opioid pain care, strong U.S. research capabilities, and a widening range of clinically validated neurostimulation and neurodiagnostic technologies.

The most attractive growth opportunities will emerge in adaptive DBS, closed-loop spinal cord stimulation, responsive epilepsy therapy, peripheral nerve stimulation, accelerated TMS, non-invasive spinal stimulation, high-density cortical electrodes, MRI-guided focused ultrasound, wearable neurotechnology, AI-enabled neural analytics, and implanted brain-computer interfaces.

Established products such as EEG, EMG, spinal cord stimulation, conventional DBS, and intraoperative neuromonitoring will continue to provide stable baseline demand. However, value creation will increasingly depend on devices that personalize therapy, generate longitudinal data, improve functional outcomes, and reduce clinical labor or avoidable healthcare utilization.

Regional growth will be led by the South because of its population scale, disease burden, and health-system expansion. The West will achieve the fastest growth due to its concentration of BCI companies, digital health capabilities, engineering expertise, venture investment, and early-adopting providers. The Northeast will remain the most influential region for clinical research and premium technology evaluation, while the Midwest will provide durable demand supported by established hospital systems and medical-device expertise.

At the state level, California, Texas, Florida, New York, Massachusetts, Pennsylvania, Illinois, Ohio, Minnesota, North Carolina, Georgia, Arizona, Michigan, Washington, and Tennessee will remain particularly important for manufacturers, investors, distributors, research organizations, and healthcare providers.

For clients evaluating the market, the central strategic question is not whether neurological technology will advance. The more important questions are which technologies will cross the boundary from investigational use into routine care, which devices will receive durable reimbursement, which companies can prove functional improvement, and how hospital systems will evaluate neurological innovation under increasing financial and workforce pressure.

Companies that combine differentiated hardware, clinically meaningful software, strong evidence, reimbursement support, specialist education, secure data infrastructure, and measurable patient benefit will define the next decade of the U.S. neurotechnology devices industry.

 

TABLE OF CONTENT

1. U.S. Neurotechnology Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Neurotechnology Device Manufacturers
1.6.2. Neural Electrode, Sensor, Semiconductor, and Component Suppliers
1.6.3. Contract Development and Manufacturing Organizations
1.6.4. Hospitals and Integrated Health Systems
1.6.5. Academic Neuroscience and Specialty Neurology Centers
1.6.6. Ambulatory Surgery Centers, Pain Clinics, and Behavioral Health Providers
1.6.7. Neurodiagnostic Laboratories and Rehabilitation Providers
1.6.8. Group Purchasing Organizations, Distributors, and Specialty Suppliers
1.6.9. Payers, Regulators, Researchers, and Clinical Decision-Makers
What this section provides: This section defines the U.S. neurotechnology devices market boundary, study scope, research methodology, assumptions, and stakeholder ecosystem so clients understand how the market is measured, segmented, validated, and forecast.

2. U.S. Neurotechnology Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size and CAGR Summary
2.8. High-Growth Product and Technology Areas
2.9. Priority Clinical Applications
2.10. Regional and State-Level Opportunity Summary
What this section provides: This section gives decision-makers a concise view of market size, growth direction, clinical demand, technology adoption, competitive intensity, regional potential, and the most attractive neurotechnology investment areas.

3. U.S. Neurotechnology Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising Burden of Neurological and Neuropsychiatric Disorders
3.1.2. Growth of the U.S. Aging Population
3.1.3. Expansion of Implantable Neuromodulation Therapies
3.1.4. Increasing Demand for Non-Opioid Chronic Pain Management
3.1.5. Growth of Treatment-Resistant Neurological and Psychiatric Conditions
3.1.6. Expansion of Outpatient Neurostimulation and Neurodiagnostic Care
3.1.7. Increasing Adoption of Closed-Loop and Adaptive Stimulation
3.1.8. Growth in Neurological Monitoring and Digital Biomarker Use
3.1.9. Expansion of Neuroscience Centers and Specialized Clinical Programs
3.2. Restraints and Their Impact Analysis
3.2.1. High Implant, Procedure, Programming, and Maintenance Costs
3.2.2. Reimbursement Variability and Prior Authorization Requirements
3.2.3. Device Revision, Explantation, and Long-Term Reliability Concerns
3.2.4. Limited Availability of Neurologists and Functional Neurosurgeons
3.2.5. Patient Selection and Referral-Pathway Limitations
3.2.6. Cybersecurity, Neural Data Privacy, and Interoperability Risks
3.3. Opportunities and Their Impact Analysis
3.3.1. Adaptive Deep Brain Stimulation
3.3.2. Closed-Loop Spinal Cord Stimulation
3.3.3. Responsive Neurostimulation for Epilepsy
3.3.4. Peripheral Nerve Stimulation Expansion
3.3.5. Accelerated Transcranial Magnetic Stimulation
3.3.6. MRI-Guided Focused Ultrasound
3.3.7. Brain-Computer Interfaces and High-Density Cortical Arrays
3.3.8. Wearable and Home-Based Neurotechnology
3.3.9. Non-Invasive Spinal Cord Stimulation and Neurorehabilitation
3.3.10. AI-Assisted Neural Signal Interpretation
3.4. Challenges and Their Impact Analysis
3.4.1. Translation of Clinical Research into Routine Care
3.4.2. Long-Term Evidence and Functional Outcome Requirements
3.4.3. Complex Device Programming and Follow-Up Workflows
3.4.4. Inconsistent Access Across Urban and Rural Markets
3.4.5. Reimbursement Readiness of Emerging Neural Interfaces
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Hospital Capital Procurement Behavior Analysis
3.8. Neuromodulation Procedure Economics Analysis
3.9. Neurodiagnostic Installed-Base and Recurring-Revenue Analysis
3.10. Patient Referral and Therapy Conversion Analysis
What this section provides: This section explains the clinical, economic, reimbursement, technological, and operational forces shaping neurotechnology demand, enabling clients to evaluate growth drivers, commercial opportunities, adoption barriers, and execution risks.

4. U.S. Neurotechnology Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.4.1. Neural Electrode and Sensor Development
4.4.2. Implantable Pulse Generator Manufacturing
4.4.3. Semiconductor, Battery, and Wireless Component Supply
4.4.4. Software, Algorithm, and Cloud Platform Development
4.4.5. Sterilization, Packaging, and Distribution
4.4.6. Clinical Implementation, Programming, and Post-Procedure Support
4.5. Impact of Digitalization and Connected Neurology
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. Class II and Class III Device Pathways
4.7.2. Premarket Approval and 510(k) Requirements
4.7.3. De Novo Classification for Emerging Neurotechnology
4.7.4. Investigational Device Exemption Pathways
4.7.5. Software as a Medical Device and Adaptive Algorithm Oversight
4.7.6. Implanted Brain-Computer Interface Regulatory Considerations
4.8. CMS Reimbursement and Coverage Landscape
4.8.1. Deep Brain Stimulation Coverage
4.8.2. Spinal Cord Stimulation Coverage
4.8.3. Vagus Nerve and Responsive Neurostimulation Coverage
4.8.4. Transcranial Magnetic Stimulation Coverage
4.8.5. Neurodiagnostic Testing Reimbursement
4.8.6. Rehabilitation and Remote Monitoring Reimbursement
4.9. Import/Export Restrictions & Tariff Impact
4.10. Government Initiatives and Public Research Programs
4.10.1. NIH Neuroscience Funding
4.10.2. BRAIN Initiative Programs
4.10.3. Department of Veterans Affairs Neurotechnology Programs
4.10.4. Department of Defense Neurotrauma and Rehabilitation Research
4.11. Impact of Escalating Geopolitical Tensions
4.12. Hospital Value Analysis Committee Decision Framework
4.13. Neural Data Privacy, Cybersecurity, and Ethical Considerations
4.14. Clinical Trial and Evidence-Generation Landscape
What this section provides: This section gives clients a complete view of the external market environment, including regulation, reimbursement, pricing, supply chains, neurological data governance, technology adoption, evidence development, and hospital procurement dynamics.

5. U.S. Neurotechnology Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
5.2. Neuromodulation and Neurostimulation Devices
5.2.1. Spinal Cord Stimulation Systems
5.2.2. Deep Brain Stimulation Systems
5.2.3. Vagus Nerve Stimulation Systems
5.2.4. Responsive Neurostimulation Systems
5.2.5. Peripheral Nerve Stimulation Systems
5.2.6. Dorsal Root Ganglion Stimulation Systems
5.2.7. Restorative Neurostimulation Systems
5.2.8. Sacral Neuromodulation Systems
5.2.9. Implantable Pulse Generators, Leads, and Programmers
5.3. Neurodiagnostic and Neurophysiological Monitoring Devices
5.3.1. Electroencephalography Systems
5.3.2. Ambulatory and Long-Term EEG Systems
5.3.3. Electromyography Systems
5.3.4. Nerve-Conduction Testing Systems
5.3.5. Evoked-Potential Monitoring Systems
5.3.6. Intraoperative Neuromonitoring Systems
5.3.7. Intracranial EEG and Cortical Recording Systems
5.3.8. Cerebral and Neurological Monitoring Devices
5.3.9. Electrodes, Sensors, Consumables, and Accessories
5.4. Neurosurgical, Navigation, and Brain-Mapping Systems
5.4.1. Stereotactic Neurosurgery Systems
5.4.2. Neuro-Navigation Platforms
5.4.3. Robotic Neurosurgical Guidance Systems
5.4.4. Surgical Planning and Image-Fusion Software
5.4.5. Intraoperative Brain-Mapping Systems
5.4.6. Cortical and Depth Electrodes
5.4.7. Functional Neurosurgery Instruments and Accessories
5.5. Neuroprosthetics and Brain-Computer Interface Devices
5.5.1. Implanted Brain-Computer Interfaces
5.5.2. Non-Invasive Brain-Computer Interfaces
5.5.3. Cortical Electrode Arrays
5.5.4. Peripheral Neural Interfaces
5.5.5. Communication and Motor-Control Interfaces
5.5.6. Sensory Restoration and Feedback Systems
5.5.7. Research-Grade Neural Recording Platforms
5.6. Neurorehabilitation and Wearable Neurotechnology
5.6.1. Robotic Neurorehabilitation Systems
5.6.2. Functional Electrical Stimulation Devices
5.6.3. Transcutaneous Spinal Stimulation Systems
5.6.4. Wearable Tremor-Therapy Devices
5.6.5. Seizure-Detection Wearables
5.6.6. Gait and Movement-Analysis Systems
5.6.7. Home-Based Neurological Rehabilitation Platforms
What this section provides: This section identifies the neurotechnology product categories and subcategories expected to generate the highest revenue, recurring demand, clinical utilization, and innovation-led growth through 2035.

6. U.S. Neurotechnology Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
6.2. Chronic Pain and Migraine Management
6.2.1. Failed Back Surgery Syndrome
6.2.2. Non-Surgical Refractory Back Pain
6.2.3. Painful Diabetic Neuropathy
6.2.4. Complex Regional Pain Syndrome
6.2.5. Peripheral Neuropathic Pain
6.2.6. Chronic Musculoskeletal Pain
6.2.7. Migraine and Headache Disorders
6.3. Movement Disorders and Neurodegenerative Diseases
6.3.1. Parkinson’s Disease
6.3.2. Essential Tremor
6.3.3. Dystonia
6.3.4. Alzheimer’s Disease and Related Dementias
6.3.5. Multiple Sclerosis-Related Functional Impairment
6.3.6. Other Movement and Gait Disorders
6.4. Epilepsy and Seizure Management
6.4.1. Refractory Focal Epilepsy
6.4.2. Generalized Epilepsy
6.4.3. Pediatric Epilepsy
6.4.4. Seizure Localization and Monitoring
6.4.5. Epilepsy Surgery Planning
6.4.6. Ambulatory and Home Seizure Monitoring
6.5. Psychiatric and Behavioral Health Disorders
6.5.1. Major Depressive Disorder
6.5.2. Treatment-Resistant Depression
6.5.3. Obsessive-Compulsive Disorder
6.5.4. Post-Traumatic Stress Disorder
6.5.5. Substance-Use and Smoking-Cessation Applications
6.5.6. Other Investigational Neuropsychiatric Applications
6.6. Stroke, Traumatic Brain Injury, Spinal Cord Injury, and Rehabilitation
6.6.1. Ischemic and Hemorrhagic Stroke Rehabilitation
6.6.2. Traumatic Brain Injury Monitoring and Recovery
6.6.3. Spinal Cord Injury Rehabilitation
6.6.4. Communication Restoration in Paralysis
6.6.5. Motor and Sensory Function Restoration
6.6.6. Post-Acute and Home-Based Neurological Rehabilitation
What this section provides: This section helps clients understand demand by neurological and neuropsychiatric use case and identify applications with strong unmet need, procedure growth, reimbursement relevance, and technology-development potential.

7. U.S. Neurotechnology Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
7.2. Hospitals and Integrated Health Systems
7.2.1. Tertiary and Quaternary Hospitals
7.2.2. Community Hospitals
7.2.3. Integrated Delivery Networks
7.2.4. Comprehensive Stroke and Epilepsy Centers
7.2.5. Hospital-Based Pain and Neuromodulation Programs
7.3. Academic Medical Centers and Neuroscience Specialty Centers
7.3.1. Functional Neurosurgery Centers
7.3.2. Movement-Disorder Centers
7.3.3. Comprehensive Epilepsy Centers
7.3.4. Neuroscience Research Hospitals
7.3.5. Pediatric Neurology and Neurosurgery Centers
7.4. Ambulatory Surgery Centers and Outpatient Specialty Clinics
7.4.1. Pain Management Clinics
7.4.2. Outpatient Neuromodulation Centers
7.4.3. Transcranial Magnetic Stimulation Clinics
7.4.4. Office-Based Neurology Practices
7.4.5. Ambulatory Neurodiagnostic Providers
7.5. Diagnostic Laboratories, Neurology Practices, and Behavioral Health Networks
7.5.1. Independent Neurodiagnostic Laboratories
7.5.2. EEG and Sleep-Testing Providers
7.5.3. Neurology Group Practices
7.5.4. Behavioral Health Networks
7.5.5. Remote Interpretation and Monitoring Providers
7.6. Rehabilitation Facilities, Home Care, and Research Institutions
7.6.1. Inpatient Rehabilitation Hospitals
7.6.2. Outpatient Physical and Occupational Therapy Centers
7.6.3. Home Healthcare Providers
7.6.4. Universities and Government Research Institutions
7.6.5. Clinical Research Organizations and Trial Sites
What this section provides: This section explains which healthcare settings, specialty providers, research organizations, and customer groups are expected to drive neurotechnology purchasing, procedure adoption, recurring monitoring, and rehabilitation demand.

8. U.S. Neurotechnology Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
8.2. Invasive Implantable Neurotechnology
8.2.1. Open-Loop Implantable Stimulation
8.2.2. Closed-Loop Implantable Stimulation
8.2.3. Sensing-Enabled Implantable Systems
8.2.4. Rechargeable Implantable Systems
8.2.5. Primary-Cell Implantable Systems
8.2.6. Implanted Neural Recording Interfaces
8.3. Non-Invasive Neurotechnology
8.3.1. Transcranial Magnetic Stimulation
8.3.2. Transcranial Electrical Stimulation
8.3.3. External Nerve Stimulation
8.3.4. Electroencephalography and Electrophysiology
8.3.5. Non-Invasive Spinal Stimulation
8.4. Minimally Invasive and Image-Guided Neurotechnology
8.4.1. MRI-Guided Focused Ultrasound
8.4.2. Percutaneous Peripheral Nerve Stimulation
8.4.3. Stereotactic Functional Neurosurgery
8.4.4. Temporary Intracranial Recording
8.4.5. Image-Guided Electrode Placement
8.5. Wearable and Portable Neurotechnology
8.5.1. Wearable Therapeutic Stimulation
8.5.2. Wearable Seizure Detection
8.5.3. Portable EEG and Neurodiagnostics
8.5.4. Gait, Tremor, and Movement Sensors
8.5.5. Home Neurorehabilitation Devices
8.6. Software-Enabled, AI-Assisted, and Closed-Loop Platforms
8.6.1. Neural Signal Analytics
8.6.2. AI-Assisted EEG Interpretation
8.6.3. Adaptive Stimulation Algorithms
8.6.4. Digital Biomarker Platforms
8.6.5. Brain-Computer Interface Decoding Software
8.6.6. Remote Programming and Monitoring Platforms
8.6.7. Clinical Decision-Support and Treatment-Planning Software
What this section provides: This section evaluates the technology architectures shaping neurological care, including implantables, non-invasive systems, image-guided platforms, wearables, neural analytics, and adaptive closed-loop workflows.

9. U.S. Neurotechnology Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
9.2. Direct Hospital and Health System Procurement
9.2.1. Capital Equipment Purchasing
9.2.2. Implant and Disposable Purchasing
9.2.3. Service, Maintenance, and Software Agreements
9.3. Integrated Delivery Network Enterprise Contracts
9.3.1. Vendor Standardization Agreements
9.3.2. Multi-Hospital Implant Contracts
9.3.3. Enterprise Neurodiagnostic Platform Agreements
9.3.4. Outcome-Based and Value-Based Contracting
9.4. Group Purchasing Organization Contracts
9.4.1. National GPO Contracts
9.4.2. Regional Purchasing Collaboratives
9.4.3. Contracted Pricing and Volume Commitments
9.5. Distributor and Specialty Supplier Sales
9.5.1. Neurodiagnostic Equipment Distributors
9.5.2. Surgical and Neuromonitoring Suppliers
9.5.3. Rehabilitation Technology Distributors
9.5.4. Consumables and Accessory Suppliers
9.6. Outpatient, Research, and Direct Specialty Procurement
9.6.1. Ambulatory Surgery Center Procurement
9.6.2. Pain Clinic and TMS Center Procurement
9.6.3. Independent Neurology Practice Procurement
9.6.4. Academic and Government Research Procurement
9.6.5. Direct-to-Provider and Subscription-Based Models
What this section provides: This section helps clients understand how neurotechnology products are purchased in the United States, including hospital contracting, IDN standardization, GPO influence, specialty distribution, outpatient purchasing, and research procurement.

10. U.S. Neurotechnology Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Procedure Volume and Neuroscience Infrastructure Analysis
10.1.4. Regional Neurological Disease Burden Analysis
10.1.5. Regional Reimbursement and Procurement Dynamics
10.1.6. Regional Clinical Trial and Neurotechnology Innovation Analysis
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region Neurotechnology Key Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Neurotechnology Key Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region Neurotechnology Key Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Neurotechnology Key Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
What this section provides: This section delivers detailed regional and state-level analysis of the U.S. neurotechnology devices market, helping clients identify neurological disease hotspots, neuroscience infrastructure, clinical-trial hubs, procurement centers, adoption patterns, and state-level commercial opportunities.

11. U.S. Neurotechnology Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking Analysis
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging Players
11.4. Product Portfolio Comparison
11.5. Clinical Evidence and Regulatory Positioning Comparison
11.6. Partnership, Licensing, and Acquisition Analysis
11.7. Company Profiles
11.7.1. Medtronic
11.7.2. Abbott Laboratories
11.7.3. Boston Scientific Corporation
11.7.4. Stryker Corporation
11.7.5. LivaNova
11.7.6. Inspire Medical Systems
11.7.7. NeuroPace
11.7.8. Globus Medical
11.7.9. Nevro Corp.
11.7.10. Integra LifeSciences
11.7.11. Natus Medical
11.7.12. Nihon Kohden America
11.7.13. Compumedics
11.7.14. Neuronetics
11.7.15. BrainsWay
11.7.16. Insightec
11.7.17. SPR Therapeutics
11.7.18. Nalu Medical
11.7.19. Saluda Medical
11.7.20. Cala Health
11.7.21. ONWARD Medical
11.7.22. Synchron
11.7.23. Neuralink
11.7.24. Precision Neuroscience
11.7.25. Blackrock Neurotech
Note: Each company profile will include company overview, neurotechnology portfolio, U.S. market strategy, financial positioning, installed base, clinical pipeline, regulatory status, reimbursement strategy, partnerships, acquisitions, product launches, and recent developments.
What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, clinical and regulatory intelligence, innovation direction, and strategic analysis of leading and emerging U.S. neurotechnology companies.

12. U.S. Neurotechnology Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Adaptive Deep Brain Stimulation
12.2.2. Closed-Loop Spinal Cord Stimulation
12.2.3. Responsive Epilepsy Neurostimulation
12.2.4. High-Density Cortical Electrode Arrays
12.2.5. Implanted Brain-Computer Interfaces
12.2.6. MRI-Guided Focused Ultrasound
12.2.7. Non-Invasive Spinal Cord Stimulation
12.2.8. AI-Assisted Neural Signal Interpretation
12.2.9. Wearable Neurotechnology and Digital Biomarkers
12.2.10. Bioelectronic Medicine and Neuroimmune Modulation
12.3. Emerging Business Trends
12.3.1. Platform-Based Neuromodulation Competition
12.3.2. Device-Software Convergence
12.3.3. Home-Based Neurological Care
12.3.4. Outcome-Based Commercial Models
12.3.5. Specialty Provider and TMS Network Consolidation
12.3.6. Strategic Partnerships Between Medtech and AI Companies
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Technology Commercialization Readiness Assessment
12.7. Reimbursement Expansion Outlook
12.8. Long-Term Neural Interface Adoption Outlook
What this section provides: This section prepares clients for future technology disruption, reimbursement evolution, market-structure changes, investment opportunities, commercialization risks, and potential neurotechnology adoption scenarios through 2035.

13. U.S. Neurotechnology Devices Market: Strategic Recommendations

13.1. Recommendations for Neurotechnology Device Manufacturers
13.2. Recommendations for Hospitals and Integrated Health Systems
13.3. Recommendations for Neuroscience and Specialty Clinical Centers
13.4. Recommendations for Investors and Private Equity Firms
13.5. Recommendations for Distributors and Channel Partners
13.6. Recommendations for New Entrants and Startups
13.7. Go-to-Market Strategy Considerations
13.8. Product Positioning and Portfolio Expansion Guidance
13.9. Regulatory and Clinical Evidence Strategy
13.10. Reimbursement and Market-Access Strategy
13.11. Physician Training and Referral-Development Strategy
13.12. State-Level Commercial Prioritization Strategy
13.13. Partnership, Licensing, and Acquisition Strategy
13.14. Neural Data, Cybersecurity, and Interoperability Strategy
What this section provides: This section converts market intelligence into actionable recommendations for product development, evidence generation, reimbursement, market access, commercialization, channel expansion, investment planning, and competitive differentiation.

14. U.S. Neurotechnology Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Market Estimate and Modeling Disclaimer
14.5. Legal Disclaimer
14.6. Third-Party Data Disclaimer
14.7. Regulatory and Reimbursement Disclaimer
14.8. Clinical and Investment Decision Disclaimer
What this section provides: This section clarifies the report’s scope limitations, data-use terms, market-modeling assumptions, legal boundaries, third-party information conditions, and forecasting limitations.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Neurotechnology Devices Market: Market Definition and Scope
TABLE 3: U.S. Neurotechnology Devices Market: Research Methodology Framework
TABLE 4: U.S. Neurotechnology Devices Market: Key Assumptions
TABLE 5: U.S. Neurotechnology Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Neurotechnology Devices Market: Stakeholder Analysis
TABLE 7: U.S. Neurotechnology Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Neurotechnology Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Neurotechnology Devices Market: Market Attractiveness Index
TABLE 10: U.S. Neurotechnology Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Neurotechnology Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Neurotechnology Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. Neurotechnology Devices Market: Drivers; Impact Analysis
TABLE 14: U.S. Neurotechnology Devices Market: Restraints; Impact Analysis
TABLE 15: U.S. Neurotechnology Devices Market: Opportunities; Impact Analysis
TABLE 16: U.S. Neurotechnology Devices Market: Challenges; Impact Analysis
TABLE 17: U.S. Neurotechnology Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 18: U.S. Neurotechnology Devices Market: Clinical Workflow Economics Matrix
TABLE 19: U.S. Neurotechnology Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 20: U.S. Neurotechnology Devices Market: Neuromodulation Procedure Economics Matrix
TABLE 21: U.S. Neurotechnology Devices Market: Neurodiagnostic Installed-Base and Recurring-Revenue Analysis
TABLE 22: U.S. Neurotechnology Devices Market: Patient Referral and Therapy Conversion Analysis
TABLE 23: U.S. Neurotechnology Devices Market: PESTEL Analysis
TABLE 24: U.S. Neurotechnology Devices Market: Porter’s Five Forces Analysis
TABLE 25: U.S. Neurotechnology Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 26: U.S. Neurotechnology Devices Market: Value Chain Analysis
TABLE 27: U.S. Neurotechnology Devices Market: Supply Chain Analysis
TABLE 28: U.S. Neurotechnology Devices Market: Digitalization and Connected Neurology Impact
TABLE 29: U.S. Neurotechnology Devices Market: Application & Innovation Landscape
TABLE 30: U.S. Neurotechnology Devices Market: FDA Regulatory Framework Analysis
TABLE 31: U.S. Neurotechnology Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 32: U.S. Neurotechnology Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 33: U.S. Neurotechnology Devices Market: Government Initiatives and Public Research Programs
TABLE 34: U.S. Neurotechnology Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 35: U.S. Neurotechnology Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 36: U.S. Neurotechnology Devices Market: Neural Data Privacy, Cybersecurity, and Ethical Considerations
TABLE 37: U.S. Neurotechnology Devices Market: Clinical Trial and Evidence-Generation Landscape
TABLE 38: U.S. Neurotechnology Devices Market: Product Category Snapshot, 2025
TABLE 39: Segment Dashboard; Definition and Scope, by Product Category
TABLE 40: U.S. Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 41: U.S. Neurotechnology Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 42: U.S. Neurotechnology Devices Market: Neuromodulation and Neurostimulation Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: U.S. Neurotechnology Devices Market: Neurodiagnostic and Neurophysiological Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: U.S. Neurotechnology Devices Market: Neurosurgical, Navigation, and Brain-Mapping Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. Neurotechnology Devices Market: Neuroprosthetics and Brain-Computer Interface Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Neurotechnology Devices Market: Neurorehabilitation and Wearable Neurotechnology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Neurotechnology Devices Market: Application Snapshot, 2025
TABLE 48: Segment Dashboard; Definition and Scope, by Application
TABLE 49: U.S. Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 50: U.S. Neurotechnology Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 51: U.S. Neurotechnology Devices Market: Chronic Pain and Migraine Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Neurotechnology Devices Market: Movement Disorders and Neurodegenerative Diseases Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. Neurotechnology Devices Market: Epilepsy and Seizure Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Neurotechnology Devices Market: Psychiatric and Behavioral Health Disorders Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Neurotechnology Devices Market: Stroke, Traumatic Brain Injury, Spinal Cord Injury, and Rehabilitation Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Neurotechnology Devices Market: End User Snapshot, 2025
TABLE 57: Segment Dashboard; Definition and Scope, by End User
TABLE 58: U.S. Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 59: U.S. Neurotechnology Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 60: U.S. Neurotechnology Devices Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. Neurotechnology Devices Market: Academic Medical Centers and Neuroscience Specialty Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. Neurotechnology Devices Market: Ambulatory Surgery Centers and Outpatient Specialty Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Neurotechnology Devices Market: Diagnostic Laboratories, Neurology Practices, and Behavioral Health Networks Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Neurotechnology Devices Market: Rehabilitation Facilities, Home Care, and Research Institutions Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Neurotechnology Devices Market: Technology Type Snapshot, 2025
TABLE 66: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 67: U.S. Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 68: U.S. Neurotechnology Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 69: U.S. Neurotechnology Devices Market: Invasive Implantable Neurotechnology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. Neurotechnology Devices Market: Non-Invasive Neurotechnology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. Neurotechnology Devices Market: Minimally Invasive and Image-Guided Neurotechnology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. Neurotechnology Devices Market: Wearable and Portable Neurotechnology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Neurotechnology Devices Market: Software-Enabled, AI-Assisted, and Closed-Loop Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Neurotechnology Devices Market: Procurement Channel Snapshot, 2025
TABLE 75: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 76: U.S. Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 77: U.S. Neurotechnology Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 78: U.S. Neurotechnology Devices Market: Direct Hospital and Health System Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: U.S. Neurotechnology Devices Market: Integrated Delivery Network Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: U.S. Neurotechnology Devices Market: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. Neurotechnology Devices Market: Distributor and Specialty Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. Neurotechnology Devices Market: Outpatient, Research, and Direct Specialty Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. Neurotechnology Devices Market: Regional Snapshot, 2025
TABLE 84: Segment Dashboard; Definition and Scope, by Region
TABLE 85: U.S. Neurotechnology Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 86: U.S. Neurotechnology Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 87: West Region U.S. Neurotechnology Devices Market: Regional Overview and Trends
TABLE 88: West Region U.S. Neurotechnology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 89: West Region U.S. Neurotechnology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 90: West Region U.S. Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 91: West Region U.S. Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 95: California Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 96: California Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 97: California Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 98: California Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 99: California Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 100: Washington Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 101: Washington Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 102: Washington Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 103: Washington Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 104: Washington Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 105: Arizona Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 106: Arizona Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 107: Arizona Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 108: Arizona Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 109: Arizona Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 110: Colorado Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 111: Colorado Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 112: Colorado Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 113: Colorado Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 114: Colorado Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 115: Oregon Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 116: Oregon Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 117: Oregon Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 118: Oregon Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 119: Oregon Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 120: Utah Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 121: Utah Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 122: Utah Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 123: Utah Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 124: Utah Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 125: Nevada Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 126: Nevada Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 127: Nevada Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 128: Nevada Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 129: Nevada Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 130: New Mexico Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 131: New Mexico Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 132: New Mexico Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 133: New Mexico Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 134: New Mexico Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 135: Idaho Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 136: Idaho Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 137: Idaho Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 138: Idaho Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 139: Idaho Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 140: Montana Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 141: Montana Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 142: Montana Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 143: Montana Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 144: Montana Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 145: Wyoming Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 146: Wyoming Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 147: Wyoming Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 148: Wyoming Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 149: Wyoming Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 150: Alaska Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 151: Alaska Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 152: Alaska Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 153: Alaska Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 154: Alaska Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 155: Hawaii Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 156: Hawaii Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 157: Hawaii Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 158: Hawaii Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 159: Hawaii Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 160: Northeast Region U.S. Neurotechnology Devices Market: Regional Overview and Trends
TABLE 161: Northeast Region U.S. Neurotechnology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 162: Northeast Region U.S. Neurotechnology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 163: Northeast Region U.S. Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 164: Northeast Region U.S. Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 165: Northeast Region U.S. Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 166: Northeast Region U.S. Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 167: Northeast Region U.S. Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 168: New York Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 169: New York Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 170: New York Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 171: New York Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 172: New York Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 173: Massachusetts Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 174: Massachusetts Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 175: Massachusetts Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 176: Massachusetts Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 177: Massachusetts Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 178: New Jersey Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 179: New Jersey Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 180: New Jersey Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 181: New Jersey Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 182: New Jersey Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 183: Pennsylvania Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 184: Pennsylvania Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 185: Pennsylvania Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 186: Pennsylvania Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 187: Pennsylvania Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 188: Connecticut Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 189: Connecticut Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 190: Connecticut Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 191: Connecticut Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 192: Connecticut Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 193: Maine Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 194: Maine Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 195: Maine Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 196: Maine Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 197: Maine Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 198: Vermont Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 199: Vermont Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 200: Vermont Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 201: Vermont Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 202: Vermont Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 203: New Hampshire Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 204: New Hampshire Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 205: New Hampshire Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 206: New Hampshire Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 207: New Hampshire Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 208: Rhode Island Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 209: Rhode Island Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 210: Rhode Island Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 211: Rhode Island Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 212: Rhode Island Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 213: Delaware Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 214: Delaware Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 215: Delaware Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 216: Delaware Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 217: Delaware Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 218: South Region U.S. Neurotechnology Devices Market: Regional Overview and Trends
TABLE 219: South Region U.S. Neurotechnology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 220: South Region U.S. Neurotechnology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 221: South Region U.S. Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 222: South Region U.S. Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 223: South Region U.S. Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 224: South Region U.S. Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 225: South Region U.S. Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 226: Texas Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 227: Texas Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 228: Texas Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 229: Texas Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 230: Texas Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 231: Florida Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 232: Florida Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 233: Florida Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 234: Florida Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 235: Florida Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 236: Georgia Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 237: Georgia Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 238: Georgia Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 239: Georgia Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 240: Georgia Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 241: North Carolina Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 242: North Carolina Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 243: North Carolina Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 244: North Carolina Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 245: North Carolina Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 246: Tennessee Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 247: Tennessee Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 248: Tennessee Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 249: Tennessee Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 250: Tennessee Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 251: South Carolina Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 252: South Carolina Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 253: South Carolina Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 254: South Carolina Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 255: South Carolina Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 256: Alabama Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 257: Alabama Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 258: Alabama Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 259: Alabama Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 260: Alabama Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 261: Mississippi Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 262: Mississippi Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 263: Mississippi Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 264: Mississippi Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 265: Mississippi Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 266: Louisiana Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 267: Louisiana Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 268: Louisiana Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 269: Louisiana Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 270: Louisiana Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 271: Arkansas Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 272: Arkansas Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 273: Arkansas Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 274: Arkansas Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 275: Arkansas Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 276: Kentucky Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 277: Kentucky Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 278: Kentucky Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 279: Kentucky Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 280: Kentucky Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 281: Oklahoma Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 282: Oklahoma Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 283: Oklahoma Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 284: Oklahoma Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 285: Oklahoma Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 286: Virginia Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 287: Virginia Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 288: Virginia Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 289: Virginia Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 290: Virginia Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 291: Maryland Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 292: Maryland Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 293: Maryland Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 294: Maryland Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 295: Maryland Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 296: West Virginia Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 297: West Virginia Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 298: West Virginia Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 299: West Virginia Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 300: West Virginia Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 301: Midwest Region U.S. Neurotechnology Devices Market: Regional Overview and Trends
TABLE 302: Midwest Region U.S. Neurotechnology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 303: Midwest Region U.S. Neurotechnology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 304: Midwest Region U.S. Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 305: Midwest Region U.S. Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 306: Midwest Region U.S. Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 307: Midwest Region U.S. Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 308: Midwest Region U.S. Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 309: Illinois Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 310: Illinois Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 311: Illinois Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 312: Illinois Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 313: Illinois Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 314: Ohio Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 315: Ohio Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 316: Ohio Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 317: Ohio Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 318: Ohio Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 319: Michigan Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 320: Michigan Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 321: Michigan Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 322: Michigan Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 323: Michigan Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 324: Minnesota Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 325: Minnesota Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 326: Minnesota Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 327: Minnesota Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 328: Minnesota Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 329: Indiana Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 330: Indiana Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 331: Indiana Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 332: Indiana Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 333: Indiana Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 334: Wisconsin Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 335: Wisconsin Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 336: Wisconsin Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 337: Wisconsin Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 338: Wisconsin Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 339: Missouri Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 340: Missouri Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 341: Missouri Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 342: Missouri Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 343: Missouri Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 344: Iowa Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 345: Iowa Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 346: Iowa Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 347: Iowa Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 348: Iowa Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 349: Kansas Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 350: Kansas Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 351: Kansas Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 352: Kansas Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 353: Kansas Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 354: Nebraska Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 355: Nebraska Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 356: Nebraska Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 357: Nebraska Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 358: Nebraska Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 359: North Dakota Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 360: North Dakota Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 361: North Dakota Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 362: North Dakota Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 363: North Dakota Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 364: South Dakota Neurotechnology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 365: South Dakota Neurotechnology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 366: South Dakota Neurotechnology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 367: South Dakota Neurotechnology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 368: South Dakota Neurotechnology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 369: U.S. Neurotechnology Devices Market: Competitive Landscape Snapshot, 2025
TABLE 370: U.S. Neurotechnology Devices Market: Key Company Market Share Analysis, 2025
TABLE 371: U.S. Neurotechnology Devices Market: Company Positioning Matrix
TABLE 372: U.S. Neurotechnology Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 373: U.S. Neurotechnology Devices Market: Clinical Evidence and Regulatory Positioning Comparison
TABLE 374: U.S. Neurotechnology Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 375: Medtronic: Company Profile
TABLE 376: Abbott Laboratories: Company Profile
TABLE 377: Boston Scientific Corporation: Company Profile
TABLE 378: Stryker Corporation: Company Profile
TABLE 379: LivaNova: Company Profile
TABLE 380: Inspire Medical Systems: Company Profile
TABLE 381: NeuroPace: Company Profile
TABLE 382: Globus Medical: Company Profile
TABLE 383: Nevro Corp.: Company Profile
TABLE 384: Integra LifeSciences: Company Profile
TABLE 385: Natus Medical: Company Profile
TABLE 386: Nihon Kohden America: Company Profile
TABLE 387: Compumedics: Company Profile
TABLE 388: Neuronetics: Company Profile
TABLE 389: BrainsWay: Company Profile
TABLE 390: Insightec: Company Profile
TABLE 391: SPR Therapeutics: Company Profile
TABLE 392: Nalu Medical: Company Profile
TABLE 393: Saluda Medical: Company Profile
TABLE 394: Cala Health: Company Profile
TABLE 395: ONWARD Medical: Company Profile
TABLE 396: Synchron: Company Profile
TABLE 397: Neuralink: Company Profile
TABLE 398: Precision Neuroscience: Company Profile
TABLE 399: Blackrock Neurotech: Company Profile
TABLE 400: U.S. Neurotechnology Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 401: U.S. Neurotechnology Devices Market: Disruptive Technologies Impact Matrix
TABLE 402: U.S. Neurotechnology Devices Market: Emerging Business Trends
TABLE 403: U.S. Neurotechnology Devices Market: Business Opportunities for Startups and Existing Players
TABLE 404: U.S. Neurotechnology Devices Market: Investment Prioritization Matrix
TABLE 405: U.S. Neurotechnology Devices Market: Technology Commercialization Readiness Assessment
TABLE 406: U.S. Neurotechnology Devices Market: Reimbursement Expansion Outlook
TABLE 407: U.S. Neurotechnology Devices Market: Long-Term Neural Interface Adoption Outlook
TABLE 408: U.S. Neurotechnology Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 409: U.S. Neurotechnology Devices Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 410: U.S. Neurotechnology Devices Market: Strategic Recommendations for Neuroscience and Specialty Clinical Centers
TABLE 411: U.S. Neurotechnology Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 412: U.S. Neurotechnology Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 413: U.S. Neurotechnology Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 414: U.S. Neurotechnology Devices Market: Go-to-Market Strategy Considerations
TABLE 415: U.S. Neurotechnology Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 416: U.S. Neurotechnology Devices Market: Regulatory and Clinical Evidence Strategy
TABLE 417: U.S. Neurotechnology Devices Market: Reimbursement and Market-Access Strategy
TABLE 418: U.S. Neurotechnology Devices Market: Physician Training and Referral-Development Strategy
TABLE 419: U.S. Neurotechnology Devices Market: State-Level Commercial Prioritization Strategy
TABLE 420: U.S. Neurotechnology Devices Market: Partnership, Licensing, and Acquisition Strategy
TABLE 421: U.S. Neurotechnology Devices Market: Neural Data, Cybersecurity, and Interoperability Strategy
TABLE 422: U.S. Neurotechnology Devices Market: Scope Limitation
TABLE 423: U.S. Neurotechnology Devices Market: Data Use Limitation
TABLE 424: U.S. Neurotechnology Devices Market: Forecasting Limitation
TABLE 425: U.S. Neurotechnology Devices Market: Market Estimate and Modeling Disclaimer
TABLE 426: U.S. Neurotechnology Devices Market: Legal Disclaimer
TABLE 427: U.S. Neurotechnology Devices Market: Third-Party Data Disclaimer
TABLE 428: U.S. Neurotechnology Devices Market: Regulatory and Reimbursement Disclaimer
TABLE 429: U.S. Neurotechnology Devices Market: Clinical and Investment Decision Disclaimer

List of Figures

FIGURE 1: U.S. Neurotechnology Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: Supply Chain Analysis
FIGURE 5: PESTEL Analysis
FIGURE 6: Porter’s Five Forces Analysis
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Clinical Workflow Economics Framework
FIGURE 11: Hospital Capital Procurement Decision Framework
FIGURE 12: U.S. Neurotechnology Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 13: U.S. Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 14: U.S. Neurotechnology Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 15: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 16: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 17: Neuromodulation and Neurostimulation Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 18: Neurodiagnostic and Neurophysiological Monitoring Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Neurosurgical, Navigation, and Brain-Mapping Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Neuroprosthetics and Brain-Computer Interface Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Neurorehabilitation and Wearable Neurotechnology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 23: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Chronic Pain and Migraine Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Movement Disorders and Neurodegenerative Diseases Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Epilepsy and Seizure Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Psychiatric and Behavioral Health Disorders Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Stroke, Traumatic Brain Injury, Spinal Cord Injury, and Rehabilitation Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 30: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Academic Medical Centers and Neuroscience Specialty Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Ambulatory Surgery Centers and Outpatient Specialty Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Diagnostic Laboratories, Neurology Practices, and Behavioral Health Networks Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Rehabilitation Facilities, Home Care, and Research Institutions Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 37: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Invasive Implantable Neurotechnology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Non-Invasive Neurotechnology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Minimally Invasive and Image-Guided Neurotechnology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Wearable and Portable Neurotechnology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Software-Enabled, AI-Assisted, and Closed-Loop Platforms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 44: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Direct Hospital and Health System Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Integrated Delivery Network Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Distributor and Specialty Supplier Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Outpatient, Research, and Direct Specialty Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 51: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: West Region U.S. Neurotechnology Devices Market Share and Leading Players, 2025
FIGURE 53: West Region Market Share Analysis by State, 2025
FIGURE 54: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: California Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Washington Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Arizona Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Colorado Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Oregon Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Utah Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Nevada Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: New Mexico Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Idaho Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Montana Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Wyoming Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Alaska Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Hawaii Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Northeast Region U.S. Neurotechnology Devices Market Share and Leading Players, 2025
FIGURE 69: Northeast Region Market Share Analysis by State, 2025
FIGURE 70: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: New York Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Massachusetts Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New Jersey Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Pennsylvania Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Connecticut Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Maine Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Vermont Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: New Hampshire Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Rhode Island Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Delaware Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: South Region U.S. Neurotechnology Devices Market Share and Leading Players, 2025
FIGURE 82: South Region Market Share Analysis by State, 2025
FIGURE 83: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Texas Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Florida Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Georgia Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: North Carolina Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Tennessee Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: South Carolina Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Alabama Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Mississippi Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Louisiana Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Arkansas Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Kentucky Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Oklahoma Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Virginia Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Maryland Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: West Virginia Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Midwest Region U.S. Neurotechnology Devices Market Share and Leading Players, 2025
FIGURE 100: Midwest Region Market Share Analysis by State, 2025
FIGURE 101: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Illinois Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Ohio Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Michigan Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Minnesota Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Indiana Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Wisconsin Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Missouri Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Iowa Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Kansas Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Nebraska Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: North Dakota Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: South Dakota Neurotechnology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 115: Company Positioning Matrix
FIGURE 116: Key Player Product Portfolio Benchmarking
FIGURE 117: Clinical Evidence and Regulatory Positioning Benchmarking
FIGURE 118: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 119: U.S. Neurotechnology Devices Innovation Roadmap
FIGURE 120: Adaptive Deep Brain Stimulation Adoption Roadmap
FIGURE 121: Closed-Loop Neuromodulation Opportunity Map
FIGURE 122: Brain-Computer Interface Commercialization Roadmap
FIGURE 123: Non-Invasive Neurotechnology Growth Roadmap
FIGURE 124: Neurorehabilitation and Wearable Technology Opportunity Map
FIGURE 125: Future Market Scenario Analysis, 2026–2035
FIGURE 126: Disruptive Technologies Impact Matrix
FIGURE 127: Emerging Business Trends Matrix
FIGURE 128: Technology Commercialization Readiness Matrix
FIGURE 129: Reimbursement Expansion Outlook
FIGURE 130: Long-Term Neural Interface Adoption Roadmap
FIGURE 131: Investment Prioritization Matrix
FIGURE 132: Strategic Growth Roadmap for U.S. Neurotechnology Device Companies
FIGURE 133: Go-to-Market Strategy Framework
FIGURE 134: Product Positioning and Portfolio Expansion Framework
FIGURE 135: Regulatory and Clinical Evidence Strategy Framework
FIGURE 136: Reimbursement and Market-Access Strategy Framework
FIGURE 137: State-Level Commercial Prioritization Map
FIGURE 138: Neural Data, Cybersecurity, and Interoperability Framework
FIGURE 139: Report Scope and Disclaimer Framework